ALK and non-small cell lung carcinoma: First, based on the concept of precision medicine, although the incidences of certain genetic alterations were low, the possibility of treatment opinion for these few patients still existed, such as tropomyosin receptor kinase (TRK) inhibitors for the patients with TRK fusion genes, and anaplastic lymphoma kinase (ALK) inhibitor for the patients with ALK-mutant non-small cell lung cancer [26, 27].